Intercept Pharmaceuticals Inc (ICPT)
20.49
-0.92 -4.30%
NASDAQ
Apr 15, 16:59
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 312.69M |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | -8.37 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | -274.88M |
Profitability | |
Gross Profit Margin (Quarterly) | 99.08% |
Profit Margin (Quarterly) | -62.63% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0% |
Price and Valuation | |
Market Cap | 676.49M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 2.155 |
PE Ratio | -- |
Price to Book Value | -- |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | -3.360 |
Free Cash Flow (Quarterly) | -17.88M |
Return on Equity | Upgrade |
View All ICPT News
News
-
WireHeadlineTime (ET)
-
MT Newswires04/08 09:00
-
Yahoo04/04 06:06
-
Yahoo03/27 11:31
-
Yahoo03/24 21:47
-
Yahoo03/15 06:06
-
SA Breaking News03/12 09:57
-
MT Newswires03/12 07:25
-
SA Breaking News03/10 08:59
-
MT Newswires03/10 08:26
-
Globe Newswire03/10 08:00
-
MT Newswires03/03 09:24
-
MT Newswires03/02 09:13
-
MT Newswires03/01 09:18
-
MT Newswires03/01 07:25
-
MT Newswires03/01 07:23
-
MT Newswires02/26 12:27
-
Yahoo02/26 12:19
-
MT Newswires02/26 11:24
-
MT Newswires02/26 10:55
-
MT Newswires02/26 08:42
View All Events
Events
Date | Type | Description |
---|---|---|
05/11/2020 08:30 EDT | Earnings Calls | Q1 2020 Earnings Call |
05/11/2020 00:00 | Earnings Results | Q1 2020 Earnings Results |
05/28/2020 10:00 EDT | Agm | 2019 Annual General Meeting |
08/10/2020 08:30 EDT | Earnings Calls | Q2 2020 Earnings Call |
08/10/2020 00:00 | Earnings Results | Q2 2020 Earnings Results |
11/09/2020 00:00 | Earnings Results | Q3 2020 Earnings Results |
11/09/2020 08:30 EST | Earnings Calls | Q3 2020 Earnings Call |
02/25/2021 00:00 | Earnings Results | Q4 2020 Earnings Results |
02/25/2021 08:30 EST | Earnings Calls | Q4 2020 Earnings Call |
05/11/2021 00:00 | Earnings Results | Q1 2021 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
- URL: https://www.interceptpharma.com
- Investor Relations URL: http://ir.interceptpharma.com/index.cfm
- HQ State/Province: New York
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Growth
- Next Earnings Release: May. 11, 2021
- Last Earnings Release: Feb. 25, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 20.49 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Top Fund Holders
Symbol | Name | Weighting |
---|---|---|
CIG4926 | CI Global Health Sciences Corp Cl Y (USD) | 5.45% |
FBT | First Trust NYSE Arca Biotech ETF | 2.85% |
F000015ZK5 | ST Healthcare Innovations 10 CA | 2.51% |
F0000155EU | ST Healthcare Innovations 9 F CA | 1.03% |
F000014EGR | ST Healthcare Innovations 8 F CA | 0.98% |
F000013KMT | ST Healthcare Innovations 7 CA | 0.86% |
XBI | SPDR® S&P Biotech ETF | 0.72% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ICPT Tweets Stocktwits
Advertisement